A melanocytic nevus is a benign localized growth of melanocytes, commonly called a mole. It belongs to the broader category of melanocytic lesions; that broader category also includes malignant processes such as melanoma. Pigment production, cellular lineage and malignant behavior are different properties.[ref]
The biology is particularly interesting because a growth-promoting molecular alteration can occur without establishing malignancy. Pamela M. Pollock and colleagues analyzed BRAF mutations in microdissected melanocytic samples. They found the substitution designated V599E in the original 2003 paper in 63 of 77 nevi, as well as in melanoma samples. Their interpretation was that pathway activation alone was insufficient for melanoma formation.[ref]
The observed nevus fraction is in that study's material. It is not a probability that an individual nevus will later become malignant: the counted event was a mutation in sampled tissue, not a future outcome followed over time. Estimating progression would require a different study design and a defined observation interval. The original mutation label is retained here as historical source terminology rather than silently equating residue-numbering conventions.
A skin biopsy supplies tissue architecture as well as cells for molecular analysis. Clinicopathological correlation relates that specimen to the lesion's observed location, extent and history, while diagnostic reproducibility asks how consistently its findings are classified. A molecular result can add evidence without replacing either the sampled architecture or the clinical question. This separation explains why detecting an alteration in a signaling gene is not by itself a complete diagnosis of malignant behavior.

Articles by others on the same topic (0)

There are currently no matching articles.